SpringWorks Therapeutics Inc

NASDAQ:SWTX   3:59:51 PM EDT
84.77
+1.78 (+2.14%)
Products, Regulatory

Precision Biosciences And Springworks Therapeutics Dose First Patient In Expanded Phase 1/2A Clinical Trial Evaluating Pbcar269a With Nirogacestat In Patients With Relapsed/Refractory Multiple M

Published: 06/28/2021 12:37 GMT
SpringWorks Therapeutics Inc (SWTX) - Precision Biosciences and Springworks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating Pbcar269a With Nirogacestat in Patients With Relapsed/refractory Multiple Myeloma.
Precision Biosciences and Springworks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating Pbcar269a With Nirogacestat in Patients With Relapsed/refractory Multiple Myeloma.